非常感谢！
美国药典USP2023(USP46-NF41 共 2 个文件夹, 22 个文件 名称修改时间大小页数阅读了该文档的用户还阅读了这些文档 p. APQP完整表格 p. MSA表格 12 p. 各种焊接作业指导书——生产部 p. 焊接产能节拍分析 p. 三元电池盒带夹具焊接作业指导书新版 6 p. 三元电子盒贴标签作业指导书-V00-2016.01...
在"炽灼残渣 (Residue on Ignition)"和"干燥失重 (Loss on Drying)"测试中,会有要求"恒重(Constant Weight)",根据《美国药典-国家处方集》(USP-NF)的规定:"恒重"表示样品连续两次炽灼或干燥后称重的差异不得超过多少重量呢? 回答: 在USP37-NF32 第二增补本的凡例...
Size价格 (元) Price (￥)库存信息 Availability品牌 Brand NANANANA 产品号/Catalog# 1ST020472-VR1 CAS#: NA MDL#: NA 产品名称: Product Name: 46 Organophosphate Insecticide Mix Solution 形态/Form: NA 颜色/Color: NA 储藏条件/Storage: NA
Thus, targeting the ubiquitination system could be an effective strategy for cancer treatment. Tosyl-L-arginine methyl ester (TAME), an APC/C inhibitor, preferentially inhibits APC/C-Cdc20 instead of APC/C-Cdh1 to inhibit mitosis in cancer cells [8]. Although the basic role of ubiquitination ...
Thus, targeting the ubiquitination system could be an effective strategy for cancer treatment. Tosyl-L-arginine methyl ester (TAME), an APC/C inhibitor, preferentially inhibits APC/C-Cdc20 instead of APC/C-Cdh1 to inhibit mitosis in cancer cells [8]. Although the basic role of ubiquitination ...
Only 1 patient had an objective response, for an ORR of 2.4%, but tumor shrinkage or stabilization was observed in 31 of 41 evaluable patients. One patient exhibited radiographic changes consistent with pseudo-progression followed by evidence of a durable complete response. The total tumor control...
We have demonstrated that enzalutamide and USP14 inhibition synergistically inhibit cell viability in breast cancer cells; this combined growth inhibition effect of the two agents is predominantly due to more effective induction of cell cycle arrest and cell apoptosis. Flow cytometry analysis showed ...
However, the only effective treatment known for NAFLD is weight loss8. Therefore, the development of targeted drugs by elucidating the molecular mechanisms underlying NAFLD is important. Different ubiquitin modifications of proteins elicit specific responses depending on the ubiquitinated substrates. In ...
Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for